Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression

Objective:  Postpartum depression (PPD) affects 10–15% of mothers. Omega‐3 fatty acids are an intriguing potential treatment for PPD. Method:  The efficacy of omega‐3 fatty acids for PPD was assessed in an 8‐week dose‐ranging trial. Subjects were randomized to 0.5 g/day (n = 6), 1.4 g/day (n = 3), o...

Full description

Saved in:
Bibliographic Details
Published inActa psychiatrica Scandinavica Vol. 113; no. 1; pp. 31 - 35
Main Authors Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Brumbach, B. H., Watchman, M., Gelenberg, A. J.
Format Journal Article
LanguageEnglish
Published Oxford, UK Munksgaard International Publishers 01.01.2006
Blackwell
Subjects
Online AccessGet full text
ISSN0001-690X
1600-0447
DOI10.1111/j.1600-0447.2005.00660.x

Cover

More Information
Summary:Objective:  Postpartum depression (PPD) affects 10–15% of mothers. Omega‐3 fatty acids are an intriguing potential treatment for PPD. Method:  The efficacy of omega‐3 fatty acids for PPD was assessed in an 8‐week dose‐ranging trial. Subjects were randomized to 0.5 g/day (n = 6), 1.4 g/day (n = 3), or 2.8 g/day (n = 7). Results:  Across groups, pretreatment Edinburgh Postnatal Depression Scale (EPDS) and Hamilton Rating Scale for Depression (HRSD) mean scores were 18.1 and 19.1 respectively; post‐treatment mean scores were 9.3 and 10.0. Percent decreases on the EPDS and HRSD were 51.5% and 48.8%, respectively; changes from baseline were significant within each group and when combining groups. Groups did not significantly differ in pre‐ or post‐test scores, or change in scores. The treatment was well tolerated. Conclusion:  This study was limited by small sample size and lack of placebo group. However, these results support further study of omega‐3 fatty acids as a treatment for PPD.
Bibliography:ark:/67375/WNG-HFKJQ1QM-4
ArticleID:ACPS660
istex:F6BD255FB5A74FD31A0399210DD005D6DE90F342
Preliminary results from this study were presented by Dr Freeman at the New Clinical Drug Evaluation Unit (NCDEU) Meeting on June 3, 2004, Phoenix, Arizona and the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 13, 2004.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0001-690X
1600-0447
DOI:10.1111/j.1600-0447.2005.00660.x